198
Participants
Start Date
March 30, 2021
Primary Completion Date
October 31, 2025
Study Completion Date
October 31, 2026
AL102
AL102 is an inhibitor of gamma secretase-mediated Notch signaling.
Placebo
Placebo to match AL102
Chris O'Brien Lifehouse, Camperdown
Peter MacCallum Cancer Centre, Melbourne
Princess Alexandra Hospital, Woolloongabba
Adelaide Cancer Centre, Kurralta Park
Universitair Ziekenhuis, Ghent
Columbia University Irving Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York
Helios Klinikum Berlin-Buch, Berlin
University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
Jefferson University Hospital, Philadelphia
Fox Chase Cancer Center, Philadelphia
IRCCS Fondazione Istituto Nazionale dei Tumori, Milan
Hospital Universitario Fundacion Jimenez Diaz, Madrid
Hospital Universitario 12 de Octubre, Madrid
Levine Cancer Institute, Charlotte
Mayo Clinic, Jacksonville
IRCCS Istituto Ortopedico Rizzoli, Bologna
Ohio State University Wexner Medical Center, Columbus
Cleveland Clinic, Cleveland
University of Michigan, Ann Arbor
Hospital Universitario Miguel Servet, Zaragoza
NorthShore University Health System, Evanston
Washington University, St Louis
Tel Aviv Sourasky Medical Center, Tel Aviv
Jefferson City Medical Group, Jefferson City
Mannheim university medical center, Mannheim
UTSW Simmons Cancer Center, Dallas
MD Anderson Cancer Center, Houston
Mayo Clinic, Pheonix
Sarcoma Oncology Research Center, Santa Monica
University of California at Los Angeles Hematology/Oncology, Santa Monica
City of Hope, Duarte
Stanford University Medical Center, Stanford
Oregon Health & Science University, Portland
Fred Hutchinson Cancer Center, Seattle
Rambam MC, Haifa
Hadassah University Hospital - Ein Kerem, Jerusalem
Massachusetts General Hospital, Boston
Universitaire Ziekenhuizen Leuven, Leuven
Oncology Institute Barzilai Medical Center, Ashkelon
Leiden University Medical Center, Leiden
Campus Bio-Medico University Hospital, Rome
The Netherlands Cancer Institute, Amsterdam
Erasmus Medisch Centrum, Rotterdam
Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw
Severance Hospital, Yonsei University Health System, Seoul
ASAN Medical Center, Seoul
Vall d´Hebrón University Hospital, Barcelona
Catalan Institute of Oncology (ICO), Barcelona
Western General Hospital, Edinburgh
Addenbrooke's Hospital, Cambridge
The Royal Marsden Hospital, London
The Christie NHS Foundation Trust, Manchester
Lead Sponsor
Immunome, Inc.
INDUSTRY